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Opiates are used therapeutically to relieve pain and, in 
some cases, to produce euphoria. The finding that mor- 
phine and other opiates bind stereoselectively to sites 
in the brain led to a search for and eventual identification 
of the endogenous ligands for the opiate receptors, 
the enkephalins, endorphins and dynorphins. These 
endogenous opiates are peptides, whereas the common 
clinically used opiates (such as morphine, fentanyl and 
methadone) are alkaloid derivatives (see Fig. 1 for repre- 
sentative structures) [l], yet they can all produce analgesia 
and modulate motor activity and behavior. 
Opiates induce their biological effects by interacting 
with membrane-associated receptors [Z]. Pharmacological 
and physiological studies have suggested that multiple 
classes of opiate receptors exist in the body that respond 
Figure 1 
differently to morphine and its analogs. To date, three 
different types of opioid receptors have been defined and 
named either for the drugs used in the studies (p, for mor- 
phine and K for ketocyclazocine) or for the anatomical 
location (6 for vas deferens). Molecular cloning studies 
confirmed that functionally distinct receptors are also 
genetically distinct, and it turns out that each receptor 
class has a number of subtypes that differ in their binding 
affinity for different drugs [l]. 
The distribution of opioid receptors in the central nervous 
system is complex, and considerable variations occur 
between different anatomical loci and species. The largest 
differences are observed with F and K receptors, especially 
K. The distribution of 6 receptors is well conserved across 
species. In general, 6 receptors, which selectively bind 
agonists such as the peptide DPDPE and the antagonist 
naltrindole, are concentrated in the forebrain and spinal 
cord, and are relatively rare in midbrain and brainstem. In 
contrast, p. and K receptors are widely distributed across 
tissues. The p. receptors, which have high affinity for most 
clinically used opiates and are characterized’by their spe- 
cific binding of the peptide DAMGO (see Fig. 1) and the 
antagonist peptide CTOP, are highly expressed through- 
out the basal ganglia and thalamic and spinal cord regions, 
where they mediate the analgesic effects of morphine. 
They are also expressed in brain regions involved in mood 
and motivation, and in brainstem regions that mediate the 
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The K receptors selectively bind the synthetic agonist 
U50 488 and the antagonist nor-BNI and they have high 
affinity for the endogenous peptide dynorphin A. They 
mediate the endocrine functions of opiates and are con- 
centrated in the cerebral cortex, striatum and hypothala- 
mus. The receptors in the limbic and mesolimbic regions 
are thought to be involved in the mood and motivational 
effects of opiates. 
The signal transduction pathway of opiate receptors 
involves GTP binding (G) proteins that negatively couple 
the receptors to adenylyl cyclase [Z] and regulate ionic 
conductances [3]. Opiates cause an inhibition of Ca2+ con- 
ductance and a potentiation of K+ currents, hyperpolar- 
izing neurons and resulting in an overall suppression of 
evoked and spontaneous neuronal activity. 
The information available from structure-function studies 
on the opioid receptors has been limited by the fact that 
the levels of receptor expression found in native tissues and 
tumor cell lines that endogenously express the receptor are 
low. The recent cloning of the genes for the opiate recep- 
tors [4] has provided new tools to identify the domains 
of the receptors involved in ligand binding, G-protein 
coupling and agonist regulation. Here, we review what has 
been learnt about the structural requirements of opioid 
receptor function. 
Cloning of the genes for the opiate receptors 
The first opiate receptor gene to be cloned, the gene for 
the 6 receptor, was cloned by expression [5,6]. The mouse 
K and 6 receptor genes were cloned by cross-hybridization 
[7], using genes for the somatostatin receptors, (a receptor 
family with high homology to the known opiate receptors 
[4]) as was the rat brain p receptor [8]. The human opioid 
receptor genes have now been cloned [l], and are very 
similar to the rodent gene in amino acid sequence. 
All the known opiate receptors are very similar to each 
other in amino acid sequence (60-70 %  identity) [4]. 
Regions of high similarity are shown in Figure 2. The 
most diverse segments of the receptors that differ signifi- 
cantly in amino acid sequence are located at the amino- 
and carboxyl termini, in the second and third extracellular 
loops and in transmembrane segment IV. These regions 
are suspected to be responsible for the functional diversity 
of these receptors. 
When expressed in mammalian cells, the cloned receptors 
have similar pharmacological specificities to the endo- 
genously expressed receptors [4]. The cloned K receptor 
binds the synthetic compound K elective l&and, U50 488, 
with high affinity, indicating that this receptor may corre- 
spond to the subtype referred to as the K~ receptor. As the 
cloned p. receptor has high affinity for naloxonazine it may 
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Comparison of predicted amino acid sequences of the mouse 6 and 
K  receptors and the rat k receptor. The amino acid sequences of the 
cloned opioid receptors are presented as a seven-transmembrane- 
spanning model. Circles represent amino acid residues. Blue circles 
represent amino acids that differ between the three cloned receptors. 
Orange circles represent amino acids that are identical among the three 
receptors. Roman numerals refer to the transmembrane spanning 
segments. Mutations of aspartates 95 (Asp95) and 128 (Asp1 28) of 
the mouse 6 receptor to asparagines are indicated. A  critical residue 
involved in the binding of the K  antagonist nor-BNI is a glutamate at 
residues 297 (Glu297). 
necessarily tentative, however, as the pharmacological 
specificities of the endogenously expressed p and K 
receptor subtypes are not clearly established [l]. 
A number of studies have suggested that subtypes of 6 
receptors can be distinguished by the antagonists BNTX 
and NTB [9]. Based on these selectivities, the cloned 
receptor corresponds to the 6, receptor [4]. Either there 
is another 6 receptor subtype gene still to be cloned or the 
6, subtype results from differences in mRNA or variations 
in protein processing. 
When studying recombinant proteins, especially in 
protein families where several members of a family may 
have similar characteristics, it is always important to check 
that the recombinant protein has the characteristics of 
the endogenqus protein. The three recombinant opiate 
receptors all couple to adenylyl cyclase, inhibiting 
forskolin-stimulated CAMP accumulation [5-81, like the 
endogenous proteins. The K receptor couples to an 
endogenous omega conotoxin sensitive (N-type) Ca2+ 
channel when expressed in PC12 cells [lo], as it does 
when endogenously expressed in neurons where it 
inhibits neurotransmitter release [lo]. The cloned p 
receptor has been reported to mediate agonist-induced 
increases in K+ conductance via an inwardly rectifying K+ 
channel [ 111, a channel important in regulating membrane 
potential and activity of neurons. Studies using oocytes 
have shown that the cloned receptors couple with the 
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recently cloned inward rectifier GIRKl [ 111, and previous 
studies [3] have reported that endogenously expressed k, 
S and K receptors are coupled to an inward rectifier to 
modulate neuronal excitability and firing rates. Thus, both 
the pharmacological and functional characteristics of the 
recombinant and endogenously expressed opiate receptors 
are similar, and data on the relationship between structure 
and function in the recombinant proteins can be taken as a 
good guide to the in vzcVo situation. 
Structure-function analysis 
Once the receptor genes were cloned, the obvious step 
was to perform mutagenesis studies to identify the 
domains of the receptors that are involved in different 
functions, especially ligand binding. Such studies may be 
useful in the rational design of new and better opiates for 
therapeutic uses. 
The first mutagenesis studies simply tested whether the 
regions that are involved in ligand binding in other 
G-protein-linked receptors were also involved in drug 
binding to opiate receptors. Most G-protein-linked recep- 
tors have conserved aspartic acid residues in transmem- 
brane-spanning regions II and III [12]. Mutations of these 
negatively charged residues to neutral asparagine have 
been found to diminish drug binding in non-opiate recep- 
tors [l&13]. It has been proposed that these residues serve 
as counter-ions to the basic regions of ligands and thus 
facilitate binding through electrostatic interactions. 
First, the functional role of a conserved aspartate (residue 
95) in the second transmembrane-spanning region of the 
S receptor in the binding of ligands was tested [ 141 (Fig. 2). 
Asp95 had been reported to be critical for Na+ to regulate 
agonist binding to other receptors, including the o12-adren- 
ergic receptor [13]. Indeed, the Asp95+Asn mutant of the 
S receptor no longer showed Na+ regulation of agonist 
binding [14], consistent with the notion that this residue is 
involved in recognition. The mutant receptor also had 
much lower affinity than the wild-type receptor for selec- 
tive agonists such as DPDPE, but its affinity for antago- 
nists was normal. Thus: Asp95 is unlikely to be part of the 
recognition site of the receptor for selective agonists, as the 
sequence of transmembrane-spanning region II is very 
similar in all three opioid receptors. It may, however, be 
important in establishing the high affinity of the receptor 
for selective agonists by slowing the rate of dissociation of 
the agonists from the receptor through electrostatic inter- 
actions. As the mutation Asp95+Asn has limited effect 
on antagonist binding, agonists and antagonists must have 
different determinants for binding to the S receptor. 
Asp128, in transmembrane-spanning region III, is another 
conserved residue that is also involved in agonist binding 
to the S receptor [15] (Fig. 2). The AsplZB+Asn receptor 
mutant no longer showed high affinity agonist binding to 
the receptor, although the effect of the mutation on antag- 
onist binding was less profound. Mutations of this residue 
in the B-adrenergic receptor [16] also significantly affected 
agonist binding. Like Asp95, Asp128 of the S receptor may 
selectively enhance the binding affinity of agonists for the 
receptor by reducing their rates of dissociation from the 
receptor. It is unclear, however, why antagonist binding is 
relatively unaffected by the Asp95-+Asn and Asp128+ 
Asn mutations, since antagonists too have cationic groups 
that are required for high-activity binding. 
Antagonist binding to K receptors 
To investigate which regions of the K receptor are involved 
in antagonist binding, Kong et al. [ 171 generated a chimeric 
K/S receptor, using the sequence from the amino terminus 
to halfway down transmembrane region I, and found that 
the amino-terminal region of the K receptor is important in 
the binding of the non-selective antagonist naloxone to the 
K receptor. Similarly, a series of K/F receptor chimeric 
receptors were used to show that that nor-BNI, the K selec- 
tive antagonist, interacts with regions in the vicinity of the 
third extracellular loop and transmembrane segment VII 
[18]. It was therefore proposed that Glu297, at the border 
between transmembrane segment VI and the third extra- 
cellular loop, is a critical amino acid in the K receptor for 
nor-BNI binding (Fig. 2). Mutation of this negatively 
charged residue to a positively charged lysine reduced the 
binding of nor-BNI to the K receptor by loo-fold. The 
affinity of nor-BNI for the k receptor is loo-fold lower than 
its affinity for the K receptor and, interestingly, the k recep- 
tor has a lysine at residue 303, corresponding to Glu297 in 
the K receptor. Hjorth et all [ 181 suggested that the Lys303 
in the p. receptor may serve to repel nor-BNI, lowering its 
affinity for the k receptor, while in the K receptor Glu297 
may serve as a counter-ion to attract the nor-BNI. The 
corresponding amino acid in the S receptor is a tryptophan 
[4]. Nor-BNI has very little affinity for the S receptor, 
perhaps because the bulky side group of the tryptophan 
prevents nor-BNI binding. 
Agonist binding to K receptors 
Chimeric receptors in which the second extracellular loop 
of the K receptor is exchanged with that of the p, receptor 
have higher affinity for the K agonist dynorphin A than 
does the p receptor ‘[19]. This may be rationalized by 
observing that the second extracellular loop of the K recep- 
tor has many more negatively charged amino acids than the 
corresponding region of either the p. or S receptors, and 
that dynorphin A has an excess of basic charges in its 
carboxy-terminal region. The specificity of this interaction 
may also come down to electrostatic interactions. 
The role of the second extracellular loop of the K recep- 
tor in agonist binding is so far unique among the opiate 
receptors. It is not unprecedented. in the wider G- 
protein-coupled receptor family, however; recent studies 
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have suggested that this region may be involved in the 
binding of selective peptide agonists to the somatostatin 
receptor SSTRl [ZO]. But the use of an extracellular loop 
to form part of a recognition site for small synthetic drugs 
is rare. Studies of the adrenergic receptors [12] suggested 
that the transmembrane-spanning regions form hydro- 
phobic pockets embedded in the membrane to which 
agonists and antagonists bind. Small molecules such 
as norepinephrine or isoproterenol, the ligands for the 
adrenergic receptors would easily fit into such pockets. 
Large peptides, such as dynorphin A (17 amino acids) or 
B-endorphin (31 amino acids) might be expected to fit 
into small pockets less well, however. Extracellular loops 
of receptors may therefore be more important as recogni- 
tion sites for large peptide agonists than they are for 
smaller classical transmitters such as norepinephrine. 
The mutagenesis studies performed on the K receptor 
suggest that antagonists and the agonist bind to physically 
distinct sites within the receptor (Fig. 3a). These drugs 
are competitive in their interaction with the receptor, 
however. This implies that either the distinct recognition 
sites overlap in three-dimensional space, or binding to 
one site induces conformational changes in the receptor 
that hinder binding to the other site. The precise way in 
which the interactions of the agonists and antagonists 
with the receptor are distinguishable is important, as dif- 
ferences here may explain differences in the functional 
consequences of their binding. 
p and 6 receptor agonist recognition sites 
Mutagenesis studies have also been conducted to identify 
regions of the l.t receptor involved in agonist binding. Wang 
etal [‘Zl] have generated a series of pJ6 receptor chimeras 
and reported that DAMGO, a peptide that is a selective k 
agonist, bound to the first extracellular loop and transmem- 
brane segment III of the lt receptor, whereas morphine 
and some other alkaloids bound to regions encompassing 
transmembrane segments V-VII and the third extracellular 
loop (Fig. 3b). These findings suggest that peptide and 
non-peptide agonists for the p, receptor bind to physically 
distinct sites within the receptor. 
This study [Zl] also suggested that the selective 6 recep- 
tor agonists DPDPE and DSLET bind to a region 
encompassing transmembrane segments V-VII and the 
third extra-cellular loop (Fig. 3~). Furthermore, two argi- 
nine residues in the third extracellular loop of the 6 
receptor were essential for DSLET binding since muta- 
tions of those residues to glutamines abolished DSLET 
binding [Zl]. Trp284, Va1296 and Va1297 in the third 
extracellular loop are critical for s-selective agonists to 
bind to the receptor [ZZ]. 
Very recently, it has been reported that aromatic amino 
acids in the transmembrane spanning regions of the 
Finure 3 
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Agonist and antagonist receptor binding sites. (a) Potential agonist 
(yellow circles) and antagonist (green circles) binding sites of the 
K  receptor. (b) Potential agonist recognition sites (magenta circles) of 
the (n. receptor. (c) Peptide agonist recognition sites are different in the 
three cloned opiate receptors. Dynorphin A  may bind to a region of the 
second extracellular loop of the K  receptor. DSLET and DPDPE may 
bind primarily to the third extracellular loop of the 6 receptor. DAMGO 
may bind to both the first and third extracellular loops of the f~. receptor. 
6 receptor also contribute to the binding of peptide S- 
selective agonists [23]. Interestingly, the binding of the 
non-peptide selective agonist BW373U86 to the 6 recep- 
tor was not clearly dependent on these aromatic amino 
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acids, nor was the binding of selective antagonists such 
as naltrindole or TIPP The non-peptide ligands might 
be expected to fit more easily into a hydrophobic pocket 
and therefore be more dependent on the presence of 
aromatic amino acids than the large peptides which carry 
more charge. 
Taken together, the mutagenesis studies suggest that 
the different opiate receptors have differences in their 
ligand binding domains, especially the peptide binding 
domains (Fig. 3~). The K selective agonist dynorphin A has 
potential binding sites in the second extracellular loop. 
DAMGO, the selective in. receptor agonist, may have recog- 
nition sites in the first extracellular loop and transmem- 
brane V and VII. The S-selective agonists DPDPE and 
DSLET appear to have sites of interaction in transmem- 
brane segments V-VII and the third extracellular loop of 
the 6 receptor. Thus all of the opiate receptors appear 
to enlist extracellular domains to give tight and specific 
peptide binding, although different extracellular loops are 
used for different peptides. The drug recognition sites of 
the opiate receptors are also found in the extracellular 
domains, which are the regions that differ most in amino 
acid sequence, consistent with the hypothesis that regions 
of sequence divergence of the receptors are responsible for 
the functional differences of the receptors. 
Intracellular domains of the opiate receptors 
Although the extracellular loops of the opiate receptors 
vary in amino acid sequence, the sequences of the intra- 
cellular loops are very similar. As expected, given this 
structural similarity, all three opiate receptors couple to 
similar cellular effector systems and modulate those effec- 
tors in a similar way. The only intracellular domain of the 
opiate receptors that differs in amino acid sequence is 
the carboxyl terminus 141. This region may not be neces- 
sary for coupling the opiate receptor to cellular effector 
systems, however, since in preliminary studies (A.D.B., 
G.B., J. Freeman, S. Li and TR., submitted) truncation 
of the k receptor carboxyl terminus did not prevent the 
receptor from coupling to adenylyl cyclase nor did trunca- 
tion of 37 amino acids from the carboxyl terminus of the 
6 receptor [24]. 
Even though the three opiate receptors all couple to similar 
effector systems, their abilities to be regulated differ. 
Desensitization and down regulation of opiate receptors 
may be critical adaptive responses in the development of 
tolerance to opiates. For many G-protein-l inked receptors, 
these responses involve post-translational modifications of 
intracellular domains. The coupling of K and 6 opiate recep- 
tors to adenylyl cyclase has been reported to undergo 
desensitization, which may be manifest as an uncoupling of 
the receptor from G  proteins [25,26]. In both cases, the 
enzyme B-adrenergic receptor kinase has been proposed to 
serve as an intermediary in the phosphorylation of the 
receptor, an event believed to facilitate the uncoupling of 
the receptor from adenylyl cyclase [25,26]. The k receptors 
are much more resistant to desensitization, since k agonists 
such as morphine and DAMGO do not appear to easily 
uncouple the receptor from the adenylyl cyclase response 
[27]. Since intracellular loops of the receptors are very 
similar in amino acid sequence, it may be that the carboxy- 
terminal region determines, at least in part, the differences 
in sensitivity to agonist regulation. 
Amino acids in the carboxyl terminus of the 6 receptor 
have been shown to be critical for the down regulation of 
the receptor following prolonged agonist treatment. The 
wild-type 6 receptor is down regulated following agonist 
treatment, but a receptor truncated by 37 amino acids 
from its carboxyl terminus was less sensitive to agonist 
regulation [24]. Thr353 was also shown to be critical for 
the down regulation of the 6 receptor. 
The p. receptor also down regulated following treatment 
with agonists such as DADLE or etorphine [28]. However,  
preliminary studies (A.D.B., G.B. and TR., unpublished 
results) with a truncated lt receptor also showed that it was 
down regulated following agonist pretreatment, suggesting 
that the carboxy-terminal amino acids of this receptor were 
not essential for the down regulation of this opiate recep- 
tor. These studies suggest that there may be structural 
differences in the opiate receptors that may contribute to 
their differential regulation by agonists. 
Conclusion 
Site-directed mutagenesis studies of the opiate receptors 
have revealed critical domains necessary for ligand binding. 
Modeling of these sites together with the known three- 
dimensional structure of the synthetic opiates should facili- 
tate the rational design of a new generation of drugs with 
improved therapeutic potency and limited side effects. 
Opiates are the most effective analgesics available. Their 
use is limited by the development of tolerance and depen- 
dence, however. Furthermore, they inhibit respiration and 
gut motility and cause nausea, which diminishes their ther- 
apeutic usefulness [l]. New drug design could overcome 
these limitations. 
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